Acadia Pharma (ACAD) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
February 27, 2018 4:08 PM EST-Fourth Quarter and Full Year 2017 Net Sales Grew to $43.6 Million and $124.9 Million, Respectively
SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its financial results for the fourth quarter and year ended December 31, 2017.
Our 2017 results reflect the robust uptake of NUPLAZID (pimavanserin) in the treatment of Parkinsons disease psychosis, said Steve Davis, ACADIAs President and Chief Executive Officer. We were also very... More
